Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
about
PET Imaging of Epigenetic Influences on Alzheimer's DiseasePredictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [CorrectedProof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's Dementia.Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progressionThe relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regressionPotential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.Quantitative multimodal multiparametric imaging in Alzheimer's disease.Structural MRI and Amyloid PET Imaging for Prediction of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment: A Meta-Analysis.18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.Advances in imaging-genetic relationships for Alzheimer's disease: clinical implications.Neuronal Network Oscillations in Neurodegenerative Diseases.Adaptive lymphocyte profiles correlate to brain Aβ burden in patients with mild cognitive impairment.A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.Olfactory Dysfunction, Olfactory Bulb Volume and Alzheimer's Disease: Is There a Correlation? A Pilot Study1.Searching for Primary Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Multivariate Follow-Up Study.[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.Immune and Imaging Correlates of Mild Cognitive Impairment Conversion to Alzheimer's Disease.Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.A Cochrane review on brain [¹⁸F]FDG PET in dementia: limitations and future perspectives.Epicentral disruption of structural connectivity in Alzheimer's disease.Inflammation, Antiinflammatory Agents, and Alzheimer's Disease: The Last 22 Years.Asymmetries of amyloid-β burden and neuronal dysfunction are positively correlated in Alzheimer's disease.A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer's Disease.
P2860
Q26776178-8340822E-3505-475E-B65C-E84B9B41166BQ27007436-EC6ED053-75A5-4703-BE8B-49BDBCF8734FQ30426397-B63F4DC9-8926-4865-A8AA-9796C3F0D5ACQ34988649-89C1E59A-C0F8-478B-BC63-3A987B856A8DQ35626520-A6EAF156-6F6F-4965-B82D-EDE7514128B2Q35864927-0525DF0A-CB93-4942-A3D0-05CAA8C89745Q36018654-E50F8112-03A4-403B-8642-28E7C8CBB88BQ36164757-998C749C-4F42-4C3F-940E-882A29B2C11BQ37706441-8B516BF7-6628-4E20-BA2B-83A3F3BD5E04Q37739887-8AD3A31F-6DDC-44E3-B6F1-5FB5C29F91BBQ38196862-F83484DE-62BD-4F03-82E5-406BC3795AFDQ38446620-1C4FE324-E758-461F-8842-F7E243FE05C4Q38657074-76FCEA09-4B5C-4E83-AB9C-32D65E30DEBAQ38697140-789CDFBC-530A-4AB3-A98E-32A202EC2333Q40984107-758CCE1B-E957-4727-A71F-2495AF5AE35AQ43347553-37388140-3DEC-4B2A-B29A-222DE03AF08BQ43597594-29A34269-1D10-460C-8C63-896DE62C5383Q47160572-2F7E714D-6D04-44C1-8365-AC7B7D72E05BQ47773740-7082EBAD-093F-4B0A-ABB7-C8C07A9FE42CQ48132965-2806CC9C-2594-459A-BCB4-11545EAF405DQ48217444-388543D4-2B45-48D1-BC4E-84FC51742EFCQ48484810-10D94D37-CD7E-494B-B21C-652E55C3EFD1Q52863124-FC912C67-1C2B-4DDC-AB66-37B86952A27EQ54980020-AD6C5EC3-E06F-4CF8-B30B-7795AFBA8658
P2860
Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Diagnosed mild cognitive impai ...... loid and neuronal dysfunction.
@ast
Diagnosed mild cognitive impai ...... loid and neuronal dysfunction.
@en
type
label
Diagnosed mild cognitive impai ...... loid and neuronal dysfunction.
@ast
Diagnosed mild cognitive impai ...... loid and neuronal dysfunction.
@en
prefLabel
Diagnosed mild cognitive impai ...... loid and neuronal dysfunction.
@ast
Diagnosed mild cognitive impai ...... loid and neuronal dysfunction.
@en
P2860
P1433
P1476
Diagnosed mild cognitive impai ...... loid and neuronal dysfunction.
@en
P2093
Hidetomo Yamasaki
Shizuo Hatashita
P2860
P304
P356
10.1371/JOURNAL.PONE.0066877
P407
P577
2013-06-14T00:00:00Z